PIM Kinase Targeted Therapies Market By Therapy Type (Monotherapy, Combination Therapies); By Target Type (Selective PIM1 Inhibitors, Dual PIM/FLT3 Inhibitors, Pan-PIM Kinase Inhibitors); By Indication (Myelofibrosis, Aggressive B-Cell Lymphoma, Multiple Myeloma, Other Hematological Malignancies); By Development Stage (Clinical Stage Therapies, Preclinical Pipeline Candidates); By End User (Hospitals, Academic Cancer Centers, Specialty Oncology Clinics, Specialty Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

PIM Kinase Targeted Therapies Market: Pipeline Progress Creates a New Specialist Oncology Opportunity

The Global PIM Kinase Targeted Therapies Market is estimated to reach USD 858.78 million in 2025 and is projected to grow to USD 1.68 billion by 2032, expanding at a CAGR of 10.1% during the forecast period, according to Strategic Market Research.

 

The market remains centred on clinical-stage oncology drugs intentionally developed to inhibit PIM1 or the wider PIM kinase family. Its 2025 value is driven primarily by clinical-development expenditure, intellectual property, licensing economics, regulatory progress and the expected commercialization of targeted therapies. Publicly validated activity is concentrated in two programs: Sumitomo Pharma’s selective PIM1 inhibitor nuvisertib in myelofibrosis and Menarini Group and Ryvu Therapeutics’ dual PIM/FLT3 inhibitor dapolsertib in relapsed or refractory aggressive B-cell lymphoma.

 

Nuvisertib Holds the Strongest Near-Term Clinical Position

Nuvisertib is the most clinically visible selective PIM1 inhibitor in active development. Its Phase 1/2 study covers three potential treatment positions in myelofibrosis: monotherapy after JAK-inhibitor failure or intolerance, addition to ruxolitinib after an inadequate response, and combination with momelotinib in previously JAK-treated patients with anaemia. These settings direct the program toward patients whose disease remains symptomatic or inadequately controlled despite established therapy.

Monotherapy findings reported in 2025 covered 77 enrolled patients. The selected higher-dose efficacy group included 18 patients, with spleen volume reduction of at least 25% reported in 22.2% and total symptom score improvement of at least 50% in 44.4%. Twenty-five of the 77 enrolled patients, or approximately 32.5%, remained on treatment for at least 12 months. This persistence rate supports the potential for recurring patient-month revenue if an oral PIM1 inhibitor enters commercial use.

The nuvisertib–momelotinib cohort produced the most important recent clinical signal for the class. Twenty-six patients had entered the cohort by the December 6, 2025 data cutoff, and 15 were efficacy-evaluable after at least 12 weeks. At week 12, 73% achieved spleen volume reduction of at least 25%, while 53% achieved a total symptom score reduction of at least 50%.

These results support an add-on position in relapsed or refractory myelofibrosis with anaemia. Larger cohorts must establish whether the responses remain durable enough to support broader development and payer acceptance. Nuvisertib is more likely to complement established JAK inhibitors than replace them, allowing the therapy to enter an existing specialist-treatment pathway where patients lose response or remain inadequately controlled.

The myelofibrosis segment is projected to increase from USD 506.68 million in 2025 to approximately USD 926.23 million by 2032, expanding at a CAGR of about 9.0%. Its market share is expected to moderate from 59% to approximately 55.1% as the lymphoma segment gains clinical maturity. Myelofibrosis would nevertheless remain the largest indication because nuvisertib has the most developed combination data, regulatory recognition across several major markets and a clearly defined post-JAK treatment position.

 

Myelofibrosis Supports Focused Orphan Commercialization

Myelofibrosis provides a small but clinically important addressable population. A U.S. SEER-based study reported an incidence of 0.32 per 100,000 person-years during 2000–2021, with incidence increasing by an average of 1.3% annually. The study included 5,403 patients and attributed 2,006 deaths, or 37.1% of the cohort, to myelofibrosis. Published U.S. and European prevalence estimates range from 2.5 to 5.7 per 100,000 people.

Applying that prevalence range to the 2025 U.S. population produces a broad pool of approximately 8,545 to 19,482 people living with myelofibrosis. The reported incidence rate represents roughly 1,094 new U.S. cases annually. The commercially relevant population is smaller because nuvisertib is being developed for intermediate- or high-risk patients with previous JAK exposure, measurable symptoms, enlarged spleen, anaemia or inadequate response to existing treatment.

The narrow treatment funnel supports a specialist orphan-drug model. Developers can concentrate clinical recruitment, physician engagement and future commercialization within leading haematology centres rather than building a broad primary-care sales network. Small patient numbers increase the importance of treatment duration, premium pricing, payer acceptance and efficient trial execution. A therapy retained for 12 months or longer can generate meaningful revenue despite limited patient volume, making the 32.5% long-duration treatment share reported in the nuvisertib study commercially relevant.

 

Dapolsertib Expands the Market into Aggressive B-Cell Lymphoma

Dapolsertib broadens the PIM kinase opportunity beyond myelofibrosis through combined inhibition of the PIM kinase family and FLT3. The JASPIS-01 Phase 2 study dosed its first patient in March 2025 and evaluates dapolsertib both as monotherapy and with the CD20xCD3 bispecific antibody glofitamab in relapsed or refractory aggressive B-cell lymphoma.

Part 1 was designed to assess safety and preliminary activity in approximately 18 patients. The registry lists estimated enrolment of 178 participants across the broader study, nearly 10 times the size of the initial Part 1 cohort. Recruitment has included France, Poland, Spain and the United Kingdom, giving the program access to specialist lymphoma centres and a wider pool of heavily treated patients.

JASPIS-01 tests two commercial positions. Bispecific-antibody-naïve patients receive dapolsertib with glofitamab, while heavily pretreated patients can receive dapolsertib alone. Both groups generally enter the study after at least two previous systemic treatment lines. The combination route offers the larger commercial opportunity because it adds dapolsertib to an established late-line therapy, but it also requires evidence that the additional drug produces enough benefit to justify higher total treatment expenditure.

The underlying diffuse large B-cell lymphoma population is materially larger than the myelofibrosis population. NCI SEER reports a U.S. incidence of 5.6 per 100,000, a death rate of 1.7 per 100,000 and five-year relative survival of 64.8%. Applied to the 2025 U.S. population, the incidence rate represents approximately 19,140 annual cases, while the death-rate proxy represents about 5,810 deaths.

Only a fraction of these patients progress through at least two systemic treatment lines and become relevant to dapolsertib. The larger disease pool nevertheless gives aggressive B-cell lymphoma stronger volume potential than myelofibrosis. Strategic Market Research estimates that the lymphoma segment will rise from approximately USD 352.10 million in 2025 to USD 754.38 million by 2032, registering a CAGR of about 11.5%. Its market share is projected to increase from 41% to approximately 44.9% as JASPIS-01 generates larger datasets and combination development expands.

 

Combination Therapies Capture the Largest Revenue Share

Combination therapies represented the leading therapy segment with an estimated 65% share in 2025, corresponding to approximately USD 558.21 million. Monotherapy accounted for the remaining 35%, or about USD 300.57 million. Combination development is present across both publicly validated active programs: nuvisertib is being evaluated with momelotinib and ruxolitinib, while dapolsertib is being combined with glofitamab.

The combination segment is projected to expand at a CAGR of approximately 11.5%, reaching nearly USD 1.20 billion by 2032. Its market share would increase to about 71.2% as development shifts toward add-on strategies that can improve responses within established treatment pathways. Monotherapy is expected to grow more moderately at approximately 7.0%, reaching around USD 482.65 million and accounting for 28.8% of the market by 2032.

Momelotinib already occupies a recognized position in intermediate- or high-risk myelofibrosis with anaemia. Nuvisertib must therefore demonstrate that adding PIM1 inhibition improves spleen response, symptoms, anaemia control or treatment durability. Strong additive benefit could support premium positioning in the post-JAK population and help the myelofibrosis combination segment maintain a major portion of total market revenue.

Glofitamab already has a late-line role in relapsed or refractory DLBCL after two or more systemic treatments. Dapolsertib’s value will depend on whether the combination improves response depth, duration or disease control compared with glofitamab alone. The optional randomized comparison in JASPIS-01 can isolate dapolsertib’s contribution and provide evidence needed for pricing, reimbursement and guideline inclusion.

Combination treatment raises revenue per patient but also increases total regimen cost. Payers will examine incremental benefit, adverse-event management, competing options and treatment duration before granting broad access. Developers that produce clear comparative evidence will have a stronger commercial position than programs supported only by small single-arm cohorts.

 

Licensing and Development Funding Generate Current Economic Value

The Menarini–Ryvu relationship shows how economic value is created before commercialization. Menarini holds global development and commercialization rights to dapolsertib, finances research and development costs, and funds Ryvu’s operational work on JASPIS-01. Ryvu remains responsible for study execution and is eligible for up to an additional EUR 80 million in milestones plus royalties.

This structure reduces Ryvu’s direct development burden while preserving future economics if the asset advances. It also gives Menarini control over one of the two leading active PIM-targeted programs. Based on validated active-agent count, the Menarini–Ryvu dapolsertib program and Sumitomo Pharma’s nuvisertib program each represent 50% of the current clinical pipeline.

Sumitomo Pharma retains control of nuvisertib and funds its ongoing development. The company has also identified partnering as an option. A co-development or licensing agreement could provide capital for larger trials, widen geographic reach and strengthen commercialization capabilities. Upfront payments, development milestones and future royalties could therefore contribute to market value before prescription-based revenue becomes the primary income stream.

 

Regulatory Progress Strengthens Commercial Readiness

Nuvisertib has received FDA orphan designation, Japanese orphan designation, FDA Fast Track designation and EU orphan designation. These actions improve regulatory interaction, support orphan-development planning and strengthen the strategic value of the program. They also reinforce the leading position of selective PIM1 inhibition, which represents an estimated 59% of the market through its primary myelofibrosis opportunity in 2025.

Dapolsertib’s current value is tied more closely to JASPIS-01 execution than to its earlier regulatory history in acute myeloid leukaemia. The move into aggressive B-cell lymphoma reflects an effort to place dual PIM/FLT3 inhibition in a setting with a larger patient pool and a clearer combination opportunity. Positive lymphoma results could accelerate the segment’s estimated 11.5% CAGR and narrow the revenue gap with myelofibrosis by 2032.

 

North America Retains the Largest Regional Share

North America led the market with an estimated 47% share in 2025, equivalent to approximately USD 403.63 million. The region benefits from nuvisertib’s extensive U.S. trial network, FDA Fast Track status, high oncology research expenditure and concentration of specialist haematology centres. The regional market is projected to expand at a CAGR of approximately 9.6%, reaching USD 766.75 million by 2032 and retaining a leading share of about 45.6%.

Nuvisertib’s U.S. study network includes City of Hope, Yale, Memorial Sloan Kettering, Duke, MD Anderson and Fred Hutch. These centres provide access to experienced investigators and could influence early prescribing and treatment-guideline adoption after approval.

Europe accounted for an estimated 31% share and USD 266.22 million in 2025. The region is projected to reach approximately USD 532.14 million by 2032, expanding at a CAGR of 10.4%. JASPIS-01 recruitment across France, Poland, Spain and the United Kingdom provides Menarini and Ryvu with a multinational development base, while EU orphan designation supports nuvisertib’s regulatory pathway.

Asia-Pacific represented approximately 17% of the market, equivalent to USD 145.99 million in 2025. It is projected to be the fastest-growing regional segment, expanding at a CAGR of about 11.0% to reach USD 303.10 million by 2032. Japan’s orphan designation for nuvisertib, Sumitomo Pharma’s regional infrastructure and expansion of specialist oncology care support this growth. The region’s market share is expected to rise to approximately 18.0% by 2032.

Other markets accounted for the remaining 5%, or approximately USD 42.94 million, in 2025 and are projected to reach USD 78.49 million by 2032 at a CAGR of about 9.0%.

 

Academic Cancer Centres Dominate the End-User Segment

Hospitals and academic cancer centres accounted for an estimated 72% market share in 2025, representing approximately USD 618.32 million. These institutions dominate clinical recruitment, complex treatment sequencing, investigational-drug administration and specialist haematology decision-making. The segment is projected to expand at a CAGR of approximately 9.7%, reaching nearly USD 1.18 billion by 2032.

Specialty oncology clinics and pharmacy channels represented approximately 28% of the market, or USD 240.46 million, in 2025. This segment is expected to grow faster at approximately 11.0%, reaching about USD 499.23 million by 2032. Its share is projected to increase to nearly 29.7% as oral PIM inhibitors move from academic trials toward specialty-pharmacy dispensing and outpatient treatment.

Treatment adoption will remain specialist-led. Haematologist-oncologists will assess prior therapy, disease progression, symptoms, blood counts, organ function, transplant suitability and payer requirements. Combination regimens will also require coordination with the supplier and administration channel of the partner therapy, particularly when an oral PIM inhibitor is paired with an infused biologic.

 

Historical Programs Raise the Competitive Proof Standard

Earlier PIM inhibitors generated clinical interest but did not establish an approved product class. Novartis evaluated PIM447 in multiple myeloma and myelofibrosis combinations, while Incyte tested the pan-PIM inhibitor INCB053914 across advanced haematological malignancies. These programs produced human safety and biological evidence without progressing into marketed therapies.

Current developers must show better selectivity, more convincing efficacy or a stronger combination role than earlier programs. Nuvisertib’s selective PIM1 profile may differentiate it from pan-PIM approaches, while dapolsertib’s dual PIM/FLT3 activity supports a separate lymphoma strategy.

Competition also extends beyond PIM inhibitors. Nuvisertib competes for a position within a myelofibrosis sequence containing multiple JAK inhibitors and emerging therapies. Dapolsertib faces CAR-T treatments, bispecific antibodies, antibody-drug conjugate regimens and chemotherapy combinations in late-line DLBCL. Future market share will therefore depend on comparative outcomes, treatment durability, safety, pricing and sequencing rather than target novelty alone.

 

Larger Clinical Datasets Will Determine the 2032 Revenue Mix

The PIM kinase targeted therapies market is moving from target validation toward indication-specific commercial development. Nuvisertib currently holds the strongest near-term position through monotherapy experience, JAK-inhibitor combinations, multinational regulatory designations and recent momelotinib data. Dapolsertib provides a second route through aggressive B-cell lymphoma, supported by Menarini funding, Ryvu execution and a planned 178-patient Phase 2 program.

Myelofibrosis is expected to retain the largest indication share, reaching approximately USD 926.23 million by 2032, while aggressive B-cell lymphoma rises to USD 754.38 million. Combination therapy is projected to become the principal revenue segment at nearly USD 1.20 billion, compared with approximately USD 482.65 million for monotherapy.

North America is projected to remain the largest regional market at about USD 766.75 million, while Asia-Pacific records the fastest regional CAGR of approximately 11.0%. Hospitals and academic cancer centres will continue to control the largest end-user share, although specialty clinics and pharmacy channels will gain revenue as oral therapies move closer to routine use.

Larger nuvisertib combination datasets, confirmation of treatment durability, dose selection, pivotal-study decisions, initial JASPIS-01 lymphoma outcomes and new licensing activity will determine how the projected USD 1.68 billion market is divided by 2032. Successful comparative evidence would support the overall 10.1% CAGR and convert approximately USD 821.22 million of forecast market expansion into specialist oncology revenue.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2025	USD 858.78 Million
Revenue Forecast in 2032	USD 1.68 Billion
Overall Growth Rate	CAGR of 10.1% (Forecast Period)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR
By Therapy Type	Monotherapy; Combination Therapies
By Target Type	Selective PIM1 Inhibitors; Dual PIM/FLT3 Inhibitors; Pan-PIM Kinase Inhibitors
By Indication	Myelofibrosis; Aggressive B-Cell Lymphoma; Multiple Myeloma; Other Hematological Malignancies
By Development Stage	Clinical Stage Therapies; Preclinical Pipeline Candidates
By End User	Hospitals; Academic Cancer Centers; Specialty Oncology Clinics; Specialty Pharmacies
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Market Drivers – Growing Need for Novel Hematology Treatments	Increasing demand for targeted therapies in relapsed or refractory blood cancers is supporting investment in PIM kinase inhibitor development.
Market Drivers – Combination Therapy Development	Integration of PIM inhibitors with JAK inhibitors, bispecific antibodies, and other oncology treatments is expanding commercial opportunities.
Market Drivers – Orphan Drug and Regulatory Support	Orphan designations, fast-track pathways, and specialist oncology development models are improving commercialization potential for niche therapies.
Customization Option	Available upon request